Gilead's HIV Quad meets primary endpoint, but not investors' expectations
This article was originally published in Scrip
Executive Summary
With the hype that has been building around Gilead's once-daily, fixed-dose, four-in-one HIV pill, dubbed Quad – emtricitabine, tenofovir disoproxil fumarate, evitegravir and cobicsta – one would think investors’ reaction to positive top-line Phase III results on 15 August would be more favourable. But alas, it was mostly disappointment, with the firm's stock losing as much as $1.25, or 3.3%, before closing $37.27, a loss of 16 cents.